The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISAL 2019 | Developments in newly diagnosed AML therapy in Europe: inspiring cooperation for tailored treatment
Bob Löwenberg, MD, PhD, of Erasmus University Medical Centre, Rotterdam, Netherlands, discusses developments in newly diagnosed acute myeloid leukemia (AML) therapy in Europe from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Löwenberg explains how these new therapies may replace or add value to the standard 7+3 chemotherapy backbone, and highlights the need for multinational cooperation to recruit sufficient numbers of patients to trials.
